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ABSTRACT 
The original designation of “Arrh th ogenic right ventricular (dysplasia/) 
cardio  o ath ”(ARVC)  as used    the scientists  ho first discovered the disease, in the  re-
genetic and pre-cardiac magnetic resonance era, to describe a new heart muscle disease 
predominantly affecting the right ventricle, whose cardinal clinical manifestation was the 
occurrence of malignant ventricular arrhythmias. Subsequently, autopsy investigations, genotype-
phenotype correlations studies and the increasing use of contrast-enhancement cardiac magnetic 
resonance showed that the fibro-fatty replacement of the myocardium represents the distinctive 
phenotypic feature of the disease that affects the myocardium of both ventricles, with left 
ventricular involvement which may parallel or exceed the severity of right ventricular 
involvement. This has led to the ne  designation of “Arrh th ogenic Cardio  o ath ” (ACM), 
that represents the evolution of the original term of ARVC. The present International Expert 
Consensus document proposes an upgrade of the criteria for diagnosis of the entire spectrum of 
the phenotypic variants of ACM. The  ro osed “Padua criteria” derive fro  the diagnostic 
approach to ACM, which has been developed over 30 years by the multidisciplinary team of basic 
researchers and clinical cardiologists of the Medical School of the University of Padua. The Padua 
criteria are a working framework to improve the diagnosis of ACM by introducing new diagnostic 
criteria regarding tissue characterization findings by contrast-enhanced cardiac magnetic 
resonance, depolarization/repolarization ECG abnormalities and ventricular arrhythmia features 
for diagnosis of the left ventricular phenotype. The proposed diagnostic criteria need to be further 
validated by future clinical studies in large cohorts of patients. 
 
INTRODUCTION 
 
The original designation of “Arrh th ogenic right ventricular (d s lasia/) cardio  o ath  
(ARVC)” was used by the scientists who first discovered the disease, in the pre-genetic and pre-
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cardiac magnetic resonance (CMR) era, to describe a new heart muscle disease predominantly 
affecting the right ventricle (RV), whose cardinal clinical manifestation was the occurrence of 
malignant ventricular arrhythmias.1-6 Subsequently, autopsy investigations, genotype-phenotype 
correlations studies and the increasing use of contrast-enhancement CMR (CE-CMR) showed that 
the fibro-fatty replacement of the myocardium represents the distinctive phenotypic feature of the 
disease and affects not only the RV but also the left ventricle. (LV).2,6-10 In the last decade there 
have been several pathologic and clinical studies that characterized the structural and electrical 
findings of the LV disease phenotype (Figure 1) and provided significant insights into diagnosis of 
left-sided disease.9-18 This has led to the ne  designation of “Arrh th ogenic Cardio  o ath  
(ACM)” that represents the evolution of the original term ARVC and reflects the modern concept 
of a biventricular muscle disease with LV involvement which may parallel or exceed the severity 
of RV involvement.19  
A recent International Expert Report has provided an extensive critical review of the 
clinical performance of the available diagnostic criteria for ACM and identified potential areas of 
improvement.2 Major limitations of the current approach to the disease diagnosis addressed by the 
document include: (i) the incomplete understanding of the genetic background of the disease and 
the large genetic noise due to several variants of uncertain significance; ii) the absence of specific 
criteria for diagnosis of the br ader spectrum of the disease phenotypes which includes left-sided 
variants; iii) the lack of tissue characterization findings by CE-CMR which offers the potential to 
identify myocardial fibrosis and play a key role for accurate diagnosis of the LV phenotype.  
The present report represents a further step towards the necessary upgrading of the criteria 
for diagnosis of the entire spectrum of phenotypic variants of ACM and provides a modern 
clinical flow-chart for the diagnosis of ACM. The proposed criteria derive from the diagnostic 
approach to ACM, which has been developed over 30 years by the multidisciplinary team of basic 
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researchers and clinical cardiologists of the Medical School of the University of Padua. The 
writing panel was enriched by the inclusion of International Experts. 
Definition and classification 
“Arrh th ogenic Cardio  o ath ” is currentl  defined as a genetic heart muscle disease 
which affects the RV, the LV or both, whose most distinctive phenotypic feature is myocardial 
scar (fibro or fibrofatty myocardial replacement) which underlies global and/or regional 
ventricular dysfunction and predisposes to potentially lethal scar-related ventricular arrhythmias, 
regardless of the severity of the systolic ventricular dysfunction.8,20 While the adjective 
“arrh th ic” refers to the nonspecific outcome of every heart disease which manifests with 
rhythm and conduction disturbances, the adjective “arrh th ogenic” (the suffix -genic according 
to its etymology from ancient Greek -γενής  eans “tending to generate” arrh th ias) is disease-
specific and denotes the distinctive propensity of ACM to develop ventricular arrhythmias, as a 
clinical reflection of the underlying fibro-fatty myocardial replacement which is the pathologic 
hallmark of the disease.  
The current classification of ACM includes the following phenotypic variants:19 (i) the 
“dominant-right” variant, i.e., the classic ARVC phenotype characterized by the predominant RV 
involvement, with no or minor LV abnormalities; (ii) the “biventricular disease” variant” 
characteri ed    the  arallel involve ent of the RV and LV; and (iii) the “dominant-left “ variant 
(also referred to as “arrh th ogenic left ventricular cardio  o ath ; ALVC”) characteri ed    
the predominant LV involvement, with no or minor RV abnormalities. 
Recently, an expert panel of the Heart Rhythm Society (HRS) has provided a broader definition of 
ACM as an “arrh th ogenic heart  uscle disorder not ex lained    ische ic, h  ertensive, or 
valvular disease.21 ACM incorporates a broad spectrum of systemic (i.e., sarcoidosis, 
amyloidosis), inflammatory (i.e., myocarditis), an infectious (i.e., Chagas disease), or genetic (e.i., 
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desmosomal ARVC or arrhythmogenic left ventricular cardiomyopathy [ALVC], lamin A/C, 
filamin-C, phospholamban) disorders and ion channel diseases”.21 According to the HRS 
document perspective, the common denominator of all these conditions is the “clinical 
presentation with symptoms or documentation of atrial fibrillation, conduction disease, and/or RV 
and/or LV arrh th ia”. There is a general agreement among the panelists of the present document 
that the “arrhythmic clinical  resentation” does not provide a pathobiologically and clinically 
appropriate rationale for a re-definition of ACM as a non-specific entity which includes a 
miscellaneous group of heterogeneous heart muscle diseases. 
 
DIAGNOSTIC CRITERIA 
 
Similar to the previous 1994 and 2010 scoring systems (Online Supplemental Tables 1),4,22 
the Padua criteria for diagnosis of ACM are based on a multi-parametric approach encompassing 
functional and structural ventricular abnormalities, tissue characterization findings, depolarization 
and repolarization electrocardiographic alterations and ventricular arrhythmias, and 
familial/genetic background which are grouped into 6 categories.  
Ta le   su  ari es the “Padua criteria” for each category for diagnosis of both the RV and LV 
involvement. The criteria rep rted in the left column represent an upgrade of the 2010 International 
Task Force (ITF) diagnostic criteria for the classic right-dominant ACM (ARVC), while those reported 
in the right column are new criteria for diagnosis of left-sided ACM (ALVC).  
The novelty of the Padua diagnostic criteria essentially consists in the introduction of tissue 
characterization by CE-CMR for detection of fibro-fatty myocardial replacement of both ventricles  
and the addition of new ECG criteria, including depolarization/ repolarization abnormalities and 
ventricular arrhythmias, specific for the LV involvement. 
The accuracy of diagnostic criteria for left-sided ACM varies according to the disease 
variant, whether biventricular or left-dominant. In the context of biventricular ACM, the disease-
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specificity of the left-sided abnormalities is ensured by the concomitant fulfilment of ITF criteria 
for the RV phenotype. Hence, in patients who meet the upgraded 2010 diagnostic criteria for the 
RV  henot  e, “ iventricular” ACM can  e reasonably diagnosed on the basis of phenotypic 
features of LV involvement, mostly morpho-functional and structural LV abnormalities. On the 
other hand, in patients with no (or minor) clinical RV abnormalities (not fulfilling the upgraded 
2010 ITF criteria), the diagnosis of left-dominant ACM (ALVC) cannot be achieved on the basis 
of the LV phenotypic criteria only. In fact, morpho-functional and structural LV abnormalities of 
ACM do not provide a sufficient disease-specificity because of the overlap with the phenotypic 
features of other heart muscle diseases such as DCM, myocarditis, or cardiac sarcoidosis. Hence, 
diagnosis of “left-do inant” ACM requires, in addition to consistent LV phenotypic features, the 
demonstration of a positive genotyping for ACM-causing gene-mutation.  
The approach used in the 1994 and 2010 ITF scoring systems for classifying morpho-
functional, structural, histological, ECG, arrhythmic, and genetic features of the ARVC as “ ajor” 
and “ inor “criteria on the basis of their disease-specificity is maintained in the Padua criteria. 
With regard to the newly proposed diagnostic criteria for LV involvement, they are classified as 
“ ajor”  hen the  are dee ed specific and necessary for diagnosis and “ inor”  hen the  are 
not required, but contribute to refine the characterization of the LV phenotype. 
At variance with genetically-determined cardiac ion channel disorders, pathogenic 
mutations, ECG abnormalities or arrhythmias are not sufficient for diagnosis of ACM, which is a 
structural heart muscle disease. By analogy with the diagnosis of hypertrophic cardiomyopathy, 
that requires demonstration of critical LV hypertrophy,23 at least one RV or LV criterion from 
categories I (i.e., morpho-functional ventricular abnormalities) or II (i.e., structural myocardial 
abnormalities), either major or minor is mandatory to reach a definite diagnosis of ACM according 
to the Padua criteria.  
I. Morpho-functional ventricular abnormalities               (i.e., global and regional ventricular dilatation and 
systolic dysfunction)  
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Right ventricle: Previous distinction of morpho-functional criteria in major and minor, based on 
the severity of global RV dilatation and dysfunction, appears more useful for prognostic than for 
diagnostic purposes and has been eliminated. The upgraded 2010 diagnostic criteria have been 
simplified to include only one major morpho-functional criterion, which is fulfilled when 
regional wall motion abnormalities, such as RV akinesia, dyskinesia or bulging are associated 
with either RV dilatation or dysfunction, regardless of their severity. In addition, a new minor 
morpho-functional criterion has been introduced which is met by the demonstration of regional 
RV wall motion abnormalities in the absence of RV dilatation and/or systolic dysfunction. The 
introduction of this latter criterion aims to increase the diagnostic sensitivity in a sizeable 
proportion of patients who show consistent RV wall motion abnormalities with normal global 
cavity size and preserved systolic function. This pattern reflects the segmental nature of RV 
lesions which may manifest as areas of fibro-fatty myocardial replacement that may alter the 
regional contractility without compromising the global hemodynamics of the RV.10,18,19,24-26 The 
“ inor” diagnostic  o er of this criterion is ex lained    the li ited s ecificit  of the su jective 
evaluation of wall motion abnormalities on echocardiography and CMR imaging.                     
In the 2010 ITF criteria, reference values of normal RV end-diastolic volumes (up to 110 
ml/m2 in men and 100 ml/m2 in women) were derived from 462 healthy controls of the 
multiethnic study of atherosclerosis (MESA), in which quantification of ventricular volumes was 
obtained using the older fast gradient echo CMR cine technique that underestimates volumes 
because of incomplete and lower endocardial border definition.4 Cardiac chamber volumes are 
more accurately measured by the modern CMR cine technique with steady-state free procession 
(SSFP) images which provides superior contrast between blood and endocardium at the 
endocardial border with less blood flow dependence.27,28 Diagnostic accuracy of both 
echocardiography and cine-CMR imaging findings is increased by the use of reference values for 
RV cavity size and systolic function normalized for age, sex and body surface area (BSA), 
according to current nomograms provided by international societies of cardiovascular imaging.28  
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It is noteworthy that the cut-off values of RV dilatation may lack specificity in the athletic 
population because physiologic adaptive changes of the RV in athlete’s heart  a   roduce an 
increase of RV volume that goes well beyond the upper limit of normality reported in the general 
population.19 In this regard, proper reference values for RV volu e in the athlete’s heart are 
currently available and should be used in the differential diagnosis of physiologic versus 
pathologic RV dilatation in athletes, especially if engaged in sports such as rowing or canoeing 
associated with the greatest RV dimensional remodeling.29 
 
Left ventricle: Demonstration of LV systolic dysfunction (by depression of LV ejection 
fraction or reduction of LV global longitudinal strain), with or without LV dilatation is a minor 
morpho-functional criterion for diagnosing “ iventricular” or “do inant- left” disease variants. 
This criterion is classified as minor because its low disease-specificity and because most patients 
show regional LV involvement without an increase of the cavity size and/or reduction of the 
global systolic function.8-19 This finding reflects the pathologic nature of ACM myocardial lesions 
which manifest as segmental and non-transmural (epi-midmyocardial) areas of fibro-fatty 
myocardial replacement, not compromising the global hemodynamics of the LV. In this regard, 
strain echocardiography has the ability to detect subtle changes and is useful in early disease.30,31 
Diagnostic accuracy is increased by the use of reference values for LV cavity size and systolic 
function normalized for age, sex and body surface area (BSA), according to current nomograms 
provided by international societies of cardiovascular imaging.27  
Accordingly, also the imaging evidence of a regional LV wall hypokinesia or akinesia 
(rarely dyskinesia) with a preserved LV global systolic function is a useful morpho-functional  
 
 
 
II. Structural myocardial abnormalities 
 (i.e., fibrous or fibro-fatty myocardial replacement ) 
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Structural myocardial abnormalities of both ventricles are routinely investigated by CE-CMR, 
which has become the leading imaging modality for ACM diagnosis due to its capability of tissue 
characterization.2,30,31 
Although direct tissue characterization is obtained only by endomyocardial biopsy (EMB), 
the invasive nature and the potential risk of serious complications (although rare and occurring in 
low volume cardiovascular centers) of this technique limit its indication to selected cases of non-
familial ACM for differential diagnosis with disease phenocopies.19 Specifically, EMB is indicated 
in probands with a sporadic form of ACM and negative genotyping, in whom the ultimate 
diagnosis depends on histologic study of the myocardium to exclude mimics such as myocarditis, 
sarcoidosis or other heart muscle disorders. Histologic demonstration of replacement-type fibrosis, 
with or without fatty tissue, on EMB samples remains a major structural criterion for diagnosis. 
The distinction of EMB findings in “major” and “minor” appears not longer justified.32 Due to 
possible sampling error, negative EMB findings do not exclude the diagnosis of ACM. Because 
the risk/benefit ratio of LV EMB is not known, at the present time this approach is not indicated 
for diagnosis of ACM. 
 
Right ventricle: Tissue characterization by CE-CMR offers the potential to demonstrate the presence 
of RV myocardial LGE/fibrosis, with or without fatty tissue replacement on dedicated sequences. 
Tissue characterization findings by CE-CMR were not included in the previous 2010 ITF criteria 
because of the limited experience in their interpretation one decade ago. The assessment of LGE or 
fatty tissue in the thin RV free wall was considered difficult to the low resolution of CMR equipment, 
the protocol design, the inversion time set to null the LV myocardium and the inversion recovery 
sequence not fat suppressed.2 Despite these limitations, the yield of RV LGE in ACM patients has 
been reported up to 88%, indicating that demonstration of LGE in the RV wall provides a significant 
added diagnostic value.26,33-35 The current availability of new generation CMR equipment with 
updated pulse sequences offers the potential to further enhance the accuracy for the identification of 
RV intramyocardial fibro-fatty scar tissue.2 Recent studies demonstrated the usefulness of combined 
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regional wall motion assessment and tissue characterization by CMR for the diagnosis of ACM. The 
highest accuracy (98%) is achieved when wall motion alterations and pre/post-contrast signal 
abnormalities are considered together.36 Accordingly, the demonstration of regional RV LGE 
(confirmed in two orthogonal planes, i.e. horizontal long-axis and short-axis views) with transmural 
involvement of the RV free wall is included in our upgrade of the 2010 criteria and classified as a 
major structural myocardial criterion. Indeed, it increases the specificity of the interpretation of 
RV wall motion abnormalities by demonstrating an underlying myocardial scar. 
 
Left ventricle: Tissue characterization findings by CE-CMR offers the unique potential to diagnose 
the condition in all affected patients with LV involvement the presence of LGE/fibrosis, localized in 
the subepicardial (less often the mid-myocardial) layers of the LV free wall and most often affecting 
the inferolateral regions, with or without septal involvement.2,8-18 The coexistence of fatty myocardial 
infiltration is often observed on dedicated sequences in the same regions of LGE or in remote LV 
areas. Most important, the typical LV remodelling pattern resulting from this fibro(-fatty) myocardial 
scar involvement consists of an hypokinetic (or normokinetic) LV, with no or mild cavity 
dilatation.2,12,13,18 LV systolic dysfunction may become more severe in the advanced stages, being 
directly related to the disease progression and increasing extent of LGE, affecting multiple segments 
of the LV free wall and septum, with a more transmural involvement.18 
Although all patients with LV involvement show LV LGE on CE- CMR, a sizeable 
proportion of them do not have associated global LV systolic dysfunction or overt wall motion 
abnormality.2,8,9,10,18,24,37,38 Hence, tissue characterization plays a key role allowing identification 
of LGE/fibrosis which is a the most sensitive feature for diagnosis of left-sided ACM. As a 
corollary, LV involvement cannot be ruled out based solely on imaging findings negative for LV 
functional abnormalities on echo, cine-CMR or angiography. Accordingly, demonstration of LV 
myocardial LGE/fibrosis in the form of a stria (or band) pattern affecting ≥1 segment (on the 
traditional “Bull’s Eye” s ste ) is a major and needed structural criterion for diagnosis of left-
sided ACM.  
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Of importance, the pattern of “junctional” LGE, which is characterized by focal/patchy 
involvement of the posterior (or less frequently anterior) ventricular septum at the site of RV 
attachment, is excluded from the diagnosis of ACM because of its non-pathologic nature.38  
 
III. ECG depolarization abnormalities 
Late potentials on SAECG are not longer included among the Padua criteria, since the use of 
SAECG technique has been abandoned by most centres because of its non-specific findings and 
limited diagnostic accuracy.2  
Right ventricle: The presence of epsilon waves in right precordial leads was classified as major ECG 
criterion in both the 1994 and the 2010 ITF criteria. However, diagnostic value of the epsilon wave has 
been questioned in the last decade, because its identification and interpretation are largely influenced 
by ECG filtering and sampling rate, giving rise to large interobserver variability.39 Among the Padua 
diagnostic criteria for ACM, epsilon waves in right precordial leads are classified as a minor ECG 
criterion, likewise the ECG pattern of a QRS delayed S- ave u stro e  ith TAD ≥55 s in right 
precordial leads (particularly if followed by negative T waves).4  
Left ventricle: Lo  QRS voltages in the li   leads (“ ea -to-peak QRS amplitude <0.5 mV) may 
predict LV involvement in the context of ACM.12-14,17,18,24 The mechanism involved in the 
reduction of QRS voltages reasonably consists of the decrease of LV myocardial mass by fibro-
fatty replacement, which mostly accounts for the generation of the electrical activity causing the 
depolarization current responsible for the QRS complex. Why it mainly affects the limb leads 
remains to be elucidated. The low sensitivity of low QRS voltages (not exceeding 30%) may be 
explained by a dose-effect relationship between myocardial replacement by fibrofatty scar and 
reduction in QRS amplitudes in limb leads. This is in keeping with the finding of significantly 
higher number of LV segments affected by LGE in patients with low QRS voltages in limb leads 
than in those without this ECG abnormality.24 Because of its low estimated specificity compared 
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with other diseases and normal control, low QRS voltages in the limb leads should be considered a 
minor ECG repolarization criterion. 
IV. ECG repolarization abnormalities 
Left ventricle: LV involvement can be predicted by the presence of T-wave inversion in the leads 
exploring the LV, mostly the left precordial leads V4-V6.8,9,18,19,24 However, this repolarization 
pattern is classified as a minor ECG criterion, because of its low disease-specificity. Most 
important, the extent of T wave inversion from right precordial (V1-V3) to left precordial leads 
(V4‐V6) may predict a more severe RV dilation/dysfunction, rather than the involvement of the 
LV. As demonstrated by a recent ECG-CMR correlation study,24 a severely dilated RV is 
displaced toward the axilla and a greater proportion of the ventricle is positioned under the ECG 
leads placed more laterally. Hence, the traditional LV leads (V4‐V6) explore the electrical activity 
of the dilated and displaced RV rather than that of the LV.  
V. Ventricular arrhythmias 
In the upgraded criteria, premature ventricular beats (PVB) are evaluated not only in terms 
of absolute number (>500 PVB per 24 hours) and complexity (non-sustained or sustained VT), but 
also with regard to the morphology of the ectopic QRS.40,41 Hence, it is important for diagnosis to 
record ventricular arrhythmia morphology on 12-ECG leads by exercise testing or 12-lead 24-hour 
Holter monitoring. 
Right ventricle: Similarly to non-sustained and sustained VT, PVBs originating from RV 
regions other than the RVOT have greater specificity for ACM (major ventricular arrhythmia 
criterion) than those from the RVOT (minor ventricular arrhythmia criterion).  
Left ventricle: Ventricular arrhythmias with a RBBB morphology (suggesting the origin 
from the LV) may be an ECG marker of LV involvement (minor ventricular arrhythmia 
criterion). 8,9,18,19,24  
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VI. Family history/molecular genetics 
According to the expert recommendations for genetic testing in ACM, genotyping is indicated to 
identify a pathogenic or likely pathogenic mutation in a proband with consistent phenotypic features of 
the disease and to apply mutation-specific cascade genetic testing for detection of gene carriers among 
family members in order to identify genetically affected individuals at a preclinical phase.2,42 The 
limitations of current understanding of the genetic basis of ACM and the high genetic noise due to 
frequent disease associated genetic variants both in the normal population and other cardiomyopathies 
pose the risk of misdiagnosis due to potential misinterpretation of molecular genetic results.43,44 
Accordingly, confirmatory genotyping to achieve a diagnosis in a patient with borderline phenotypic 
manifestations may be considered in selected cases provided that the results are interpreted by experts on 
the molecular genetics of ACM.45 
While in patients with biventricular ACM is the concomitant fulfilment of RV diagnostic  
criteria to guarantee the disease-specificity of the left-sided abnormalities, in patients with  
left-dominant ACM and no clinically detectable RV involvement, demonstration of a pathogenic  
mutation in ACM-related genes (major criterion) is necessary for diagnosis, because it is the most specific 
finding linking the LV phenotypic features to ACM. 
 
DIAGNOSIS OF PHENOTYPIC VARIANTS OF ACM 
 
Figure 3 illustrates the proposed score for diagnosis of phenotypic variants of ACM. A 
definite diagnosis of “dominant right” (“ARVC”) variant is met in patients fulfilling the RV 
criteria; i.e., 2 major, 1 major and 2 minor, or 4 minor criteria from different categories (≥1 
criterion, either major or minor, from categories I or II nedeed), in the absence of LV involvement. 
The diagnosis of “biventricular” variant (i.e., involvement of both ventricles) is met in patients 
fulfilling the RV criteria for “definite” or “ orderline” diagnosis (i.e., 1 major and 1 minor, or 3 
minor criteria from different categories; ≥1 criterion, either major or minor, from categories I or II 
nedeed), who also show morpho-functional and/or structural abnormalities of the LV according to 
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the present diagnostic criteria. The diagnosis of “dominant-left” (“ALVC”) variant is met in 
patients who show structural (with or without morpho-functional) abnormalities of the LV, plus 
demonstration of a ACM-causing gene-mutation, in the absence of morpho-functional and/or 
structural signs of RV involvement (not fulfilling the RV criteria for either “definite” or 
“ orderline” diagnosis). Figure 3 summarizes the proposed flow-chart for clinical diagnosis of 
ACM, which is based on the Padua protocol for management of ACM probands and families. 
CONCLUSIONS 
Over the last decade there has been an increasing awareness that the phenotypic spectrum 
of ACM was broader than previously expected and included biventricular and left-dominant 
variants. The lack of specific ITF diagnostic criteria resulted in the under-recognition of patients 
with the non-classic ARVC phenotype. The Padua criteria represent a working framework to 
improve the diagnosis of ACM with the aim to fill the gap of previous 1994 and 2010 ITF criteria, 
by introducing new diagnostic criteria regarding CE-CMR tissue characterization findings, 
depolarization/repolarization ECG abnormalities and ventricular arrhythmia features for diagnosis 
of the LV phenotype. The proposed diagnostic criteria need to be validated by further clinical 
studies in large cohorts of patients. Future research should focus on a better understanding of the 
genetic background, the identification of diagnostic biomarkers and the evaluation of natural 
history, risk stratification and management of patients diagnosed with left-sided ACM. 
The following are the supplementary data related to this article. 
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Table 1. “Padua criteria” for diagnosis of Arrhythmogenic Cardiomyopathy 
Category 
 
Right ventricle  
(upgraded 2010 ITF diagnostic 
criteria)  
 
Left ventricle 
(new diagnostic criteria) 
 
I. Morpho-
functional 
ventricular 
abnormalities 
By echocardiography, CMR or 
angiography:  
 
Major 
 Regional RV akinesia, 
dyskinesia, or bulging 
 
  plus one of the following: 
  
- global RV 
dilatation (increase of 
RV EDV according to 
the imaging test specific 
monograms for age and 
gender) 
- global RV 
systolic dysfunction 
(reduction of RV EF 
according to the imaging 
test specific monograms 
for age, sex, and BSA) 
   
Minor  
 Regional RV akinesia, 
dyskinesia or aneurysm of RV 
free wall 
 
By echocardiography, CMR or 
angiography:  
 
Minor 
 Global LV systolic 
dysfunction (depression of LV 
EF according to the imaging test 
monograms for age and sex, and 
BSA or reduction of 
echocardiographic global 
longitudinal strain), with or 
without LV dilatation (increase 
of LV EDV according to the 
imaging test specific 
monograms for age, sex, and 
BSA) 
 
Minor 
 Regional LV 
hypokinesia or akinesia of LV 
free wall, septum, or both 
 
 
 
 
II. Structural 
myocardial 
abnormalities  
By CE-CMR:  
Major 
 Transmural LGE (stria 
pattern) of  
≥  RV region(s) (inlet, outlet, 
and apex in 2 orthogonal views) 
 
By EMB (limited indications): 
Major 
   Fibrous replacement of the 
myocardium in ≥  sa  le, 
with or without fatty tissue 
By CE-CMR: 
Major  
   LV LGE (stria pattern) of ≥  
Bull’s Eye segment(s) (in 2 
orthogonal views) of the free wall 
(subepicardial or midmyocardial), 
septum, or both (excluding septal 
junctional LGE)  
 
 
 
 
 
III. 
Repolarization 
abnormalities 
Major 
 Inverted T waves in right 
precordial leads (V1,V2, and V3) or 
beyond in individuals with 
complete pubertal development (in 
the absence of complete RBBB)  
 
Minor 
 Inverted T waves in left 
precordial leads (V4-V6) (in the 
absence of complete LBBB)  
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Category 
 
Right ventricle  
(upgraded 2010 ITF diagnostic 
criteria)  
 
Left ventricle 
(new diagnostic criteria) 
 
Minor 
   Inverted T waves in leads V1 and 
V2 in individuals with completed 
pubertal development (in the 
absence of complete RBBB) 
 
   Inverted T waves in V1,V2 ,V3 
and V4 in individuals with 
completed pubertal development in 
the presence of complete RBBB. 
 
IV. 
Depolarization 
abnormalities 
Minor 
 Epsilon wave (reproducible 
low-amplitude signals  
between end of QRS complex to 
onset of the T wave) in  
the right precordial leads (V1 to 
V3)  
 
 Terminal activation 
duration of QRS ≥55  s measured 
from the nadir of the S wave to the 
end of the QRS, including R’, in 
V1, V2, or V3 (in the absence of 
complete RBBB) 
Minor 
 Low QRS voltages (<0.5 
mV peak to peak ) in limb leads 
(in the absence of obesity, 
emphysema, or pericardial 
effusion) 
V. Ventricular 
arrhythmias 
Major 
 Frequent ventricular 
extrasystoles (>500 per 24 
hours), non-sustained or 
sustained ventricular 
tachycardia of LBBB 
morphology 
  
Minor 
 Frequent ventricular 
extrasystoles (>500 per 24 
hours), non-sustained or 
sustained ventricular 
tachycardia of LBBB 
morphology with inferior axis 
(“RV T  attern”)  
Minor 
 Frequent ventricular 
extrasystoles (>500 per 24 
hours), non-sustained or 
sustained ventricular 
tachycardia with a RBBB 
morphology (excluding the 
“fascicular  attern”)  
VI. Family  
history/genetics 
       Major 
 
       ACM confirmed in a first-degree relative who meets 
       diagnostic criteria 
        ACM confirmed pathologically at autopsy or surgery in a 
       first-degree relative 
       Identification of a pathogenic or likely pathogenetic 
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Category 
 
Right ventricle  
(upgraded 2010 ITF diagnostic 
criteria)  
 
Left ventricle 
(new diagnostic criteria) 
 
       ACM mutation in the patient under evaluation 
 
       Minor 
        History of ACM in a first-degree relative in whom it is not 
       possible or practical to determine whether the family member 
       meets diagnostic criteria 
        Premature sudden death (<35 years of age) due to suspected 
       ACM in a first-degree relative 
        ACM confirmed pathologically or by diagnostic 
       criteria in second-degree relative 
 
 
ACM=arrhythmogenic cardiomyopathy; BSA=body surface area; EDV=end diastolic volume; EF=ejection 
fraction; ITF= International Task Force; LBBB= left bundle-branch block; LGE= late gadolinium 
enhancement; LV=left ventricle; RBBB= right bundle-branch block; RV=right ventricle; RVOT=right 
ventricular outflow tract 
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FIGURE LEGENDS 
 
 
Figure 1. Electrocardiographic, CE-CMR imaging, and histological features of a 
representative patient with a predominant-left ACM related to a DSP gene defect. Basal 
ECG showing low voltages in limb leads and flattened T‐ waves in the inferolateral leads (A). 
Post‐ contrast CMR images in long‐ axis (B) and short‐ axis (C) views showing normal LV 
cavity size and subepicardial LGE (white arrows) involving the LV free wall (boxed area) and 
se tu  (“ring- li e”  attern), fro   asal to a ical regions.  istologic exa ination of the  oxed 
area showing fibro‐ fatty myocardial replacement affecting the subepicardial LV layer 
(Heidenhain trichrome stain) (D); close up detailing residual myocytes embedded within 
fibrous and fatty tissue (E.E stain) (E). ACM= arrhythmogenic cardiomyopathy; CMR=cardiac 
magnetic resonance; DSP= Desmoplakin gene; LGE=late gadolinium enhancement; LV=left 
ventricular. From Cipriani et al.18 
Figure 2. Diagnosis of phenotypic variants of ACM. Although dominant-right (ARVC) and 
biventricular disease variants can be diagnosed in those patients fulfilling RV and LV 
phenotypic criteria, the diagnosis of dominant- left (ALVC ), without clinically demonstrable 
RV abnormalities, needs demonstration of an ACM-causing gene-mutation, in association with 
a consistent LV phenotype. § In family members with a consistent LV phenotype the diagnosis 
of ALVC may be also made if ACM is confirmed in a first-degree relative either clinically on 
the base of diagnostic criteria or pathologically at autopsy or surgery.  
Figure 3. Proposed flow-chart for clinical diagnosis of ACM. Patients with a suspicion of ACM 
because of family history, symptoms, ECG abnormalities, ventricular arrhythmias, or imaging 
features undergo a non-invasive clinical evaluation which includes 12-lead ECG, echocardiography, 
exercise testing, and 24-hour Holter monitoring. In addition, morpho-functional ventricular 
abnormalities and structural myocardial tissue alterations are routinely investigated by contrast-
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enhanced CMR, which has become the leading imaging modality for diagnosis and characterization 
of the disease phenotype, with particular reference with the left-sided variants. Transthoracic two-
dimensional echocardiography is indicated as part of the initial evaluation of a patient with 
suspected ACM. The availability of echocardiographic findings at initial evaluation is important in 
view of the subsequent serial imaging follow-up. Right ventricular angiography is not of additional 
diagnostic value and is reserved to patients in whom endomyocardial biopsy is planned. Cardiac 
catheterization is indicated when oxygen saturation measurement is required for differential 
diagnosis between ACM and congenital heart diseases with a left to right shunt, if the CMR 
findings are inconclusive. Clinical and molecular genetic screening is performed for identification 
of the ACM-causing genetic defect and pre-clinical diagnosis among family members. Concurrent 
with the family genotyping, all relatives should have a comprehensive clinical study including CE-
CMR for individual evaluation of the disease phenotype and co-segregation analysis with the 
identified gene-variant. Based on molecular genetic testing, the disease can be related to ACM-
causing mutations of either desmosomal or non-desmosomal genes. Gene elusive, either familial or 
non-familial disease, require further evaluation to exclude disease mimics, including overlapping 
phenotype with other genetic heart muscle diseases such as familial dilated cardiomyopathy, 
congenital phenocopies such as left-to-right shunt or Ebstein anomaly, and acquired phenocopies 
such as idiopathic dilated cardiomyopathy, cardiac sarcoidosis, myocarditis, pulmonary artery 
hypertension, or Chagas disease.  
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Figure 2 
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HIGHLIGHTS 
 The original designation of “Arrh th ogenic right ventricular d s lasia/cardio  o ath W  as 
used to describe a heart muscle disease predominantly affecting the right ventricle whose 
cardinal clinical manifestation was the occurrence of malignant ventricular arrhythmias; 
 Subsequent investigations showed that the fibro-fatty replacement of the myocardium represents 
the distinctive phenotypic feature of the disease and affects not only the right ventricle but also, 
and sometimes predominantly, the left ventricle; 
 The main limitation of the 2010 International Task Force diagnostic criteria was the lack of 
specific criteria for diagnosis of the broader spectrum of the disease phenotypes which includes 
left-sided variants; 
 The present report represents a proposal for upgrading of the arrhythmogenic cardiomyopathy 
diagnostic criteria encompassing the entire spectrum of phenotypic variants (dominant-right, 
biventricular and dominant- left). 
Journal Pre-proof
